LL schreef op 28 juli 2022 09:45:
Takeda kwartaal cijfers HAE update:In Rare Genetics & Hematology, Takeda focuses on several areas of high unmet medical need. In hereditary angioedema,
Takeda aspires to transform the treatment paradigm, including through TAKHZYRO, with continued investment in lifecycle
management programs including evaluating TAKHZYRO in Bradykinin-mediated angioedema with normal C1-inhibitor.
Sales of TAKHZYRO (for hereditary angioedema) were 34.0 billion JPY, an increase of 8.6 billion JPY,
or 33.7%, versus the same period of the previous fiscal year primarily due to expansion of the prophylactic market,
continued geographic expansion and strong patient uptak
bron: